Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches. Exclusive to Pieris, Anticalins promise to address high-unmet medical needs and expand the potential of targeted therapeutics.
Anticalins are recombinantly engineered versions of human lipocalins, low-molecular weight polypeptides that naturally bind, store and transport a wide spectrum of molecules. To make Anticalin-brand proteins, Pieris makes discrete changes to those lipocalin amino acid positions responsible in endogenous ligand binding, thereby redirecting specificity away from the natural ligand and to virtually any target of interest.
The company has a diverse pipeline of Anticalin Therapeutics and has active, multi-program R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila and Stelis Biopharma.
Privately held, Pieris has been funded by premier biotechnology-focused venture capital, with OrbiMed Advisors as its lead investor. Additional investors include Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, Global Life Science Ventures, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.